PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28912887-10	2017	Conclusions: rSj16 has protective effects on DSS-induced colitis, effects mediated mainly by PPAR-alpha signaling pathway inhibition.	rsj16	13-18	peroxisome proliferator activated receptor alpha	Mus musculus	93-103
28912887-0	2017	rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-alpha Signaling Pathway.	rsj16	0-5	peroxisome proliferator activated receptor alpha	Mus musculus	61-71
27640151-5	2016	By using antibody neutralization experiments and IL-10-deficient (knockout) mice, we confirmed that the inhibitory effect of rSj16 on LPS-induced BMDCs is due to its induction of IL-10 production.	rsj16	125-130	interleukin 10	Mus musculus	49-54
28912887-8	2017	Moreover, DSS-induced colitis mice treated with rSj16 displayed changes in the expression levels of specific genes in the colon and show the crucial role of peroxisome proliferator activated receptor alpha (PPAR-alpha) signaling pathway.	rsj16	48-53	peroxisome proliferator activated receptor alpha	Mus musculus	157-205
28912887-8	2017	Moreover, DSS-induced colitis mice treated with rSj16 displayed changes in the expression levels of specific genes in the colon and show the crucial role of peroxisome proliferator activated receptor alpha (PPAR-alpha) signaling pathway.	rsj16	48-53	peroxisome proliferator activated receptor alpha	Mus musculus	207-217
28912887-9	2017	PPAR-alpha activation diminished the therapeutic effects of rSj16 in DSS-induced colitis mice, indicating that the PPAR-alpha signaling pathway plays a crucial role in DSS-induced colitis development.	rsj16	60-65	peroxisome proliferator activated receptor alpha	Mus musculus	0-10
28912887-9	2017	PPAR-alpha activation diminished the therapeutic effects of rSj16 in DSS-induced colitis mice, indicating that the PPAR-alpha signaling pathway plays a crucial role in DSS-induced colitis development.	rsj16	60-65	peroxisome proliferator activated receptor alpha	Mus musculus	115-125
27640151-5	2016	By using antibody neutralization experiments and IL-10-deficient (knockout) mice, we confirmed that the inhibitory effect of rSj16 on LPS-induced BMDCs is due to its induction of IL-10 production.	rsj16	125-130	interleukin 10	Mus musculus	179-184
27640151-6	2016	To understand how rSj16 induces the production of IL-10, we analyzed the protein sequence and revealed two potential nuclear localization signals (NLS) in Sj16.	rsj16	18-23	interleukin 10	Mus musculus	50-55
27640151-8	2016	The results of our study concluded that the ability of rSj16 to inhibit DC functions is IL-10 dependent which is operated by IL-10R signal pathway.	rsj16	55-60	interleukin 10	Mus musculus	88-93
22712636-5	2012	An increase in CD4(+)CD25(+) T cells was observed both in splenic cells from mice injected with rSj16 and the cells pretreated with rSj16, respectively.	rsj16	96-101	CD4 antigen	Mus musculus	15-18
23319265-5	2013	Furthermore, apoptosis induced by rSj16 was confirmed by 4,6-diamidino-2-phenylindole nuclear staining assay and annexin V/propidium iodide double staining.	rsj16	34-39	annexin A5	Mus musculus	113-122
23319265-7	2013	rSj16 treatment induced an increase in the activity of caspase 3, 6, and 9, and expression of pro-apoptotic Bax.	rsj16	0-5	caspase 3	Mus musculus	55-74
23319265-7	2013	rSj16 treatment induced an increase in the activity of caspase 3, 6, and 9, and expression of pro-apoptotic Bax.	rsj16	0-5	BCL2-associated X protein	Mus musculus	108-111
23319265-8	2013	Meanwhile, the decreased expression of anti-apoptotic Bcl-2 was observed after rSj16 treatment.	rsj16	79-84	B cell leukemia/lymphoma 2	Mus musculus	54-59
23319265-9	2013	Taken together, our results implied that rSj16 can inhibit proliferation by inducing G0/G1 cell cycle arrest and apoptosis of murine myeloid leukemia cells via activation of the caspase-mediated mechanism by regulating the expression of Bcl-2 family.	rsj16	41-46	caspase 6	Mus musculus	178-185
23319265-9	2013	Taken together, our results implied that rSj16 can inhibit proliferation by inducing G0/G1 cell cycle arrest and apoptosis of murine myeloid leukemia cells via activation of the caspase-mediated mechanism by regulating the expression of Bcl-2 family.	rsj16	41-46	B cell leukemia/lymphoma 2	Mus musculus	237-242
22712636-5	2012	An increase in CD4(+)CD25(+) T cells was observed both in splenic cells from mice injected with rSj16 and the cells pretreated with rSj16, respectively.	rsj16	132-137	CD4 antigen	Mus musculus	15-18
22712636-7	2012	Additionally, rSj16-treated bone marrow dendritic cells (BMDCs) demonstrate an immature phenotype and play a role in the conversion of CD4(+)CD25(-) T cells into suppressive CD4(+)CD25(+) regulatory T cells.	rsj16	14-19	CD4 antigen	Mus musculus	135-138
22712636-7	2012	Additionally, rSj16-treated bone marrow dendritic cells (BMDCs) demonstrate an immature phenotype and play a role in the conversion of CD4(+)CD25(-) T cells into suppressive CD4(+)CD25(+) regulatory T cells.	rsj16	14-19	CD4 antigen	Mus musculus	174-177
20204135-5	2010	Further studies indicated that rSj16 induced macrophage differentiation of the WEHI-3B JCS cells, and arrested the cell cycle in the G1/G0 and G2/M phases.	rsj16	31-36	allograft inflammatory factor 1	Mus musculus	133-145
22017401-9	2012	Our study also reveals that rSj16 suppresses lipopolysaccharide-induced major histocompatibility complex II expression and IL-12 production, while increasing IL-10 production in resident peritoneal macrophages.	rsj16	28-33	interleukin 10	Mus musculus	158-163
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	interleukin 1 beta	Mus musculus	102-110
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	interleukin 6	Mus musculus	112-116
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	interleukin 23, alpha subunit p19	Mus musculus	125-130
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	tumor necrosis factor	Mus musculus	136-145
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	interleukin 10	Mus musculus	209-214
22281546-9	2012	rSj16 can also inhibit the LPS-induced activation of NF-kappabeta.	rsj16	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	53-65
21039614-5	2010	After administration of rSj16 (recombinant Sj16) in vivo, paw swelling reduced significantly and in a dose-dependent manner, the level of TNF-alpha, IL-1beta and NO decreased and IL-10 in the serum increased.	rsj16	24-29	tumor necrosis factor	Rattus norvegicus	138-147
21039614-5	2010	After administration of rSj16 (recombinant Sj16) in vivo, paw swelling reduced significantly and in a dose-dependent manner, the level of TNF-alpha, IL-1beta and NO decreased and IL-10 in the serum increased.	rsj16	24-29	interleukin 1 beta	Rattus norvegicus	149-157
21039614-5	2010	After administration of rSj16 (recombinant Sj16) in vivo, paw swelling reduced significantly and in a dose-dependent manner, the level of TNF-alpha, IL-1beta and NO decreased and IL-10 in the serum increased.	rsj16	24-29	interleukin 10	Rattus norvegicus	179-184
21039614-6	2010	In vitro, rSj16 reversed the augmented surface expression of CD80, CD86, CD54 and OX6 induced by lipopolysaccharide (LPS) in bone marrow-derived DCs (BMDCs), whereas endocytotic capacity of rSj16-treated dendritic cell (DC) was profoundly increased.	rsj16	10-15	Cd80 molecule	Rattus norvegicus	61-65
21039614-6	2010	In vitro, rSj16 reversed the augmented surface expression of CD80, CD86, CD54 and OX6 induced by lipopolysaccharide (LPS) in bone marrow-derived DCs (BMDCs), whereas endocytotic capacity of rSj16-treated dendritic cell (DC) was profoundly increased.	rsj16	10-15	CD86 molecule	Rattus norvegicus	67-71
21039614-6	2010	In vitro, rSj16 reversed the augmented surface expression of CD80, CD86, CD54 and OX6 induced by lipopolysaccharide (LPS) in bone marrow-derived DCs (BMDCs), whereas endocytotic capacity of rSj16-treated dendritic cell (DC) was profoundly increased.	rsj16	10-15	intercellular adhesion molecule 1	Rattus norvegicus	73-77
18804475-8	2009	In vivo, rSj16 dramatically suppressed the recruitment of thioglycollate-mediated leukocytes to the peritoneal cavity of BALB/c mice, accompanied by marked up-regulation of IL-10 and IL-1RA transcripts, and down-regulation of IL-12p35, IL-1 beta and MIP-2 transcripts in peritoneal cells.	rsj16	9-14	interleukin 10	Mus musculus	173-178
18804475-8	2009	In vivo, rSj16 dramatically suppressed the recruitment of thioglycollate-mediated leukocytes to the peritoneal cavity of BALB/c mice, accompanied by marked up-regulation of IL-10 and IL-1RA transcripts, and down-regulation of IL-12p35, IL-1 beta and MIP-2 transcripts in peritoneal cells.	rsj16	9-14	interleukin 1 receptor antagonist	Mus musculus	183-189
18804475-8	2009	In vivo, rSj16 dramatically suppressed the recruitment of thioglycollate-mediated leukocytes to the peritoneal cavity of BALB/c mice, accompanied by marked up-regulation of IL-10 and IL-1RA transcripts, and down-regulation of IL-12p35, IL-1 beta and MIP-2 transcripts in peritoneal cells.	rsj16	9-14	interleukin 12a	Mus musculus	226-234
18804475-8	2009	In vivo, rSj16 dramatically suppressed the recruitment of thioglycollate-mediated leukocytes to the peritoneal cavity of BALB/c mice, accompanied by marked up-regulation of IL-10 and IL-1RA transcripts, and down-regulation of IL-12p35, IL-1 beta and MIP-2 transcripts in peritoneal cells.	rsj16	9-14	interleukin 1 beta	Mus musculus	236-245
18804475-8	2009	In vivo, rSj16 dramatically suppressed the recruitment of thioglycollate-mediated leukocytes to the peritoneal cavity of BALB/c mice, accompanied by marked up-regulation of IL-10 and IL-1RA transcripts, and down-regulation of IL-12p35, IL-1 beta and MIP-2 transcripts in peritoneal cells.	rsj16	9-14	chemokine (C-X-C motif) ligand 2	Mus musculus	250-255